These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20609175)

  • 61. Transfer factor: a potential agent for immunotherapy of cancer.
    Meier CR; LoBuglio AF
    World J Surg; 1977 Sep; 1(5):617-23. PubMed ID: 272085
    [No Abstract]   [Full Text] [Related]  

  • 62. How gut microbes are joining the fight against cancer.
    Guglielmi G
    Nature; 2018 May; 557(7706):482-484. PubMed ID: 29795257
    [No Abstract]   [Full Text] [Related]  

  • 63. International Melanoma Research Congress--Foundation for Melanoma Research. 21-24 June 2003, Philadelphia, PA, USA.
    Swart GW
    IDrugs; 2003 Aug; 6(8):752-4. PubMed ID: 12971393
    [No Abstract]   [Full Text] [Related]  

  • 64. ASO Author Reflections: The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients: A Potential Paradigm Shift in Management.
    van Akkooi ACJ; Spillane AJ
    Ann Surg Oncol; 2020 Jul; 27(7):2201-2202. PubMed ID: 32382889
    [No Abstract]   [Full Text] [Related]  

  • 65. The association between beta-blockers and melanoma survival: evidence of absence or absence of evidence?
    Hollestein LM; Nijsten T
    Br J Dermatol; 2014 Apr; 170(4):764-5. PubMed ID: 24734945
    [No Abstract]   [Full Text] [Related]  

  • 66. In This Issue: Translational Opportunities for Antibodies: Therapeutics, Biomarkers, and Novel Targets.
    Bot A; Kumar H
    Int Rev Immunol; 2016 Jul; 35(4):291-293. PubMed ID: 27797621
    [No Abstract]   [Full Text] [Related]  

  • 67. Letter from the Editor.
    Pedersen AE
    Immunopharmacol Immunotoxicol; 2017 Feb; 39(1):1. PubMed ID: 28071184
    [No Abstract]   [Full Text] [Related]  

  • 68. Cancer immunotherapy trials: leading a paradigm shift in drug development.
    Emens LA; Butterfield LH; Hodi FS; Marincola FM; Kaufman HL
    J Immunother Cancer; 2016; 4():42. PubMed ID: 27437105
    [No Abstract]   [Full Text] [Related]  

  • 69. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
    Sanmamed MF; Chen L
    Cell; 2019 Jan; 176(3):677. PubMed ID: 30682374
    [No Abstract]   [Full Text] [Related]  

  • 70. Circulating protein and antibody biomarker for personalized cancer immunotherapy.
    Yuan J
    J Immunother Cancer; 2016; 4():46. PubMed ID: 27532021
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
    Ellebaek E; Engell-Noerregaard L; Iversen TZ; Froesig TM; Munir S; Hadrup SR; Andersen MH; Svane IM
    Cancer Immunol Immunother; 2012 Oct; 61(10):1791-804. PubMed ID: 22426890
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cancer immunotherapy.
    Gajewski TF
    Mol Oncol; 2012 Apr; 6(2):242-50. PubMed ID: 22248437
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
    Piérard GE; Aubin F; Humbert P
    Dermatol Res Pract; 2012; 2012():182157. PubMed ID: 22046181
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pseudoprogression and Immune-Related Response in Solid Tumors.
    Chiou VL; Burotto M
    J Clin Oncol; 2015 Nov; 33(31):3541-3. PubMed ID: 26261262
    [No Abstract]   [Full Text] [Related]  

  • 76. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
    Bakacs T; Mehrishi JN
    Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
    Gajewski TF
    Pigment Cell Melanoma Res; 2010 Oct; 23(5):580-1. PubMed ID: 20609175
    [No Abstract]   [Full Text] [Related]  

  • 78. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.